Pancreatic cancer action network - Join us
Clinical Trial
Finder
Retrieving Trials
Retrieving Trials...

Back to Trial Search

Phase I Study of Ixazomib and Erlotinib in Advanced Solid Tumor Patients

Summary

NOTE: This trial is currently enrolling in the dose escalation cohort. The purpose of this phase I study is to evaluate the safety and find the highest tolerable dose of the combination of ixazomib and erlotinib that can be given to patients with advanced solid tumors.

General Information

NCT#: NCT02942095
Study ID: 2015-0688
Trial Phase: Phase I

Trial Sponsor: M.D. Anderson Cancer Center, Takeda Oncology
Therapies Used in This Trial: Erlotinib, Ixazomib

Request a Healthcare Provider account to access Trial Eligibility and Site Information.

View Details

An authorized Healthcare Provider account is required to access Trial Eligibility and Site Information. Already have an account?

Request an Account


  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account.
  • In order to view this information, you need to be signed in as a Health Care Provider.
  • In order to see the trial eligibility criteria, you need to be signed in as a Health Care Provider.
  • This information is restricted to validated Health Care Providers.

Eligibility



-------------------------------------------------------------------------------------------

  • In order to view this information, you need to be signed in as a Health Care Provider.
  • You need to be signed in as a Health Care Provider. Please request an account by clicking on the Request button.
  • ------------------------------------------------------------------------------------------------------
  • In order to view this information, you need to be signed in as a Health Care Provider. You are currently not authorized.

Site Information


Back to Trial Search